Thursday, October 15, 2015 2:38:27 PM
Manzo Pharmaceuticals starts human laboratory testing of the company's lactose intolerance probiotic, Lacto-Freedom(TM)Thursday 10/15/2015 09:00 AM ET - PR Newswire via Dow Jones News
MILFORD, Pa., Oct. 15, 2015 /PRNewswire/ -- Manzo Pharmaceuticals, Inc. (OTCPink:MNZO), today announced that in conjunction with Celprogen, Inc., the human laboratory testing of the company's exciting probiotic, Lacto-Freedom(TM) has begun. Celprogen has started sending out the test samples of the product marking the start of the much anticipated human testing, which is the last major step before the product can be manufactured and released to the public.
FEATURED Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement • May 8, 2024 9:05 AM
Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM
Kona Gold Beverages, Inc. Achieves April Revenues Exceeding $586,000 • KGKG • May 8, 2024 8:30 AM
Epazz plans to spin off Galaxy Batteries Inc. • EPAZ • May 8, 2024 7:05 AM
Moon Equity Holdings, Corp. Announces Acquisition of Wikolo, Inc. • MONI • May 7, 2024 9:48 AM
Cannabix Technologies Launches New Compact Breath Logix Workplace Series and Prepares for Delivery to South Africa • BLOZF • May 7, 2024 8:51 AM